Fresenius Kabi Introduces Levofloxacin IV in Freeflex® Container

  Fresenius Kabi Introduces Levofloxacin IV in Freeflex® Container

Business Wire

LAKE ZURICH, Ill. -- August 29, 2013

Fresenius Kabi USA announced today the availability of Levofloxacin in 5%
Dextrose Injection in freeflex® containers.

(Photo: Business Wire)

(Photo: Business Wire)

Freeflex® is an innovative container designed for infusion solutions that has
been marketed globally since 2005 and in the U.S. since 2008. Freeflex’s
multilayer polyolefin film is PVC-free, plasticizer-free, non-DEHP and
designed for easy handling with enhanced safety, environmental performance in

“The introduction of Levofloxacin using the freeflex technology expands our
market leading anti-infective business with a ready to use formulation and
provides customers with a new choice in serving their patients,” said John
Ducker, president and CEO of Fresenius Kabi USA.

Levofloxacin is a fluoroquinolone antibacterial indicated for use in the
treatment of bacterial infections caused by susceptible bacteria, including
pneumonia, bronchitis, skin infections, urinary tract infections, prostatitis
and anthrax. Fresenius Kabi USA received FDA approval for Levofloxacin in 5%
Dextrose Injection in June, 2013.

According to IMS, in 2012 the total U.S. market for Levofloxacin premix was
$69 million.

About Fresenius Kabi

Fresenius Kabi ( is a leading global health care
company that focuses on pharmaceuticals and medical devices used to care for
critically and chronically ill patients inside and outside the hospital. The
company’s products include intravenous specialty and generic medicines,
infusion therapies, clinical nutrition and related medical devices. Fresenius
Kabi expanded its presence in the United States in 2008 with the acquisition
of APP Pharmaceuticals, Inc. and again in 2012 with the acquisition of Fenwal
Inc. The company's roots go back more than 100 years to the founding of
Fresenius SE, in Bad Homburg, Germany, where the company is headquartered

In the United States, APP, a division of Fresenius Kabi USA, LLC markets a
broad portfolio of injectable and specialty pharmaceutical products with a
focus on the oncology, anti-infective, anesthetic/analgesic and critical care
markets for use in hospitals, long-term care facilities, alternate care sites
and clinics. For more information, visit

Forward Looking Statement

To the extent this release contains forward-looking statements that are
subject to various risks and uncertainties. Future results could differ
materially from those described in these forward-looking statements due to
certain factors, e.g. changes in business, economic and competitive
conditions, regulatory reforms, results of clinical trials, foreign exchange
rate fluctuations, uncertainties in litigation or investigative proceedings,
and the availability of financing. Fresenius does not undertake any
responsibility to update the forward-looking statements in this release.

Photos/Multimedia Gallery Available:



Matt Kuhn
Fresenius Kabi
Press spacebar to pause and continue. Press esc to stop.